Clinical Trials List
2024-03-15 - 2032-12-31
Phase III
Not yet recruiting4
Recruiting2
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Shang-Hung Chen 無
- Zhu-Jun Loh 無
- Chun-Hui Lee 無
- Jui-Hung Tsai 無
- Wei-Pang Chung 無
- 楊舜如 無
- 魏慈慧 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Wen-Chi Shen 無
- Wen-Ling Kuo 無
- Chan-Keng Yang 無
- 何蕙余 無
- 周旭桓 無
- Mengting Peng 無
- 沈士哲 無
- Yung-Chang Lin 無
- Chi-Chang Yu 無
- 阮昱翔 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
1200 participants
